Effect of tumor-stroma ratio in prognosis evaluation of tumor

Abstract

Abstract:Tumorstroma ratio is the ratio of tumor cells and stromal tissue. It can be evaluated through HEstained sections. Usually a 50% cutoff value is taken. TSR is stratified as stroma rich (TSR<50%) and stroma poor (TSR≥50%). The different prognosis between the two groups can be assessed. Several previous studies show that TSR is an independent prognostic factor for colon carcinoma, breast cancer, esophageal squamous cell carcinoma, cervical carcinoma and nonsmall cell lung cancer; patients with stromarich tumor suffer worse prognosis. The cause might be that tumor cells could activate stroma cells while activated stroma cells could promote the growth, infiltration and metastasis of tumors. And tumor stroma should be recognized as an indispensible participant in progression and invasion of carcinoma.

Key words:Neoplasmas,Prognosis,Tumor-stroma ratio

CAI Xian-Lei-；Wu-Jian-；Zheng-Shu-Sen. Effect of tumor-stroma ratio in prognosis evaluation of tumor[J]. Journal of International Oncology, 2015, 42(4): 284-287.

References

［1］ Pietras K, Ostman A. Hallmarks of cancer: interactions with the tumor stroma［J］. Exp Cell Res, 2010, 316(8):13241331. ［2］ Astekar M, Metgud R, Sharma A, et al. Hidden keys in stroma: Unlocking the tumor progression［J］. J Oral Maxillofac Pathol, 2013, 17(1):8288. ［3］ Karagiannis GS, Poutahidis T, Erdman SE, et al. Cancerassociated fibroblasts drive the progression of metastasis through both paracrine and mechanical pressure on cancer tissue［J］. Mol Cancer Res, 2012, 10(11):14031418. ［4］ Bremnes RM, Donnem T, AlSaad S, et al. The role of tumor stroma in cancer progression and prognosis: emphasis on carcinomaassociated fibroblasts and nonsmall cell lung cancer［J］. J Thorac Oncol, 2011, 6(1):209217. ［5］ Huijbers A, Tollenaar RA, v Pelt GW, et al. The proportion of tumorstroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial［J］. Ann Oncol, 2013, 24(1):179185. ［6］ de Kruijf EM, van Nes JG, van de Velde CJ, et al. Tumorstroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triplenegative carcinoma patients［J］. Breast Cancer Res Treat, 2011, 125(3):687696. ［7］ Dekker TJ, van de Velde CJ, van Pelt GW, et al. Prognostic significance of the tumorstroma ratio: validation study in nodenegative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (10854)［J］. Breast Cancer Res Treat, 2013, 139(2):371379. ［8］ Wang K, Ma W, Wang J, et al. Tumorstroma ratio is an independent predictor for survival in esophageal squamous cell carcinoma［J］. J Thorac Oncol, 2012, 7(9):14571461. ［9］ Courrech Staal EF, Smit VT, van Velthuysen ML, et al. Reproducibility and validation of tumour stroma ratio scoring on oesophageal adenocarcinoma biopsies［J］. Eur J Cancer, 2011, 47(3):375382. ［10］ Liu J, Liu J, Li J, et al. Tumorstroma ratio is an independent predictor for survival in early cervical carcinoma［J］. Gynecol Oncol, 2014, 132(1):8186. ［11］王兆峰, 刘红兵, 赵仁德, 等. 肿瘤间质比是非小细胞肺癌独立的预后因素［J］. 中国肺癌杂志, 2013, 16(4): 191196. ［12］ Hemmings C. Is carcinoma a mesenchymal disease? The role of the stromal microenvironment in carcinogenesis［J］. Pathology, 2013, 45(4):371381. ［13］ Curry JM, Sprandio J, Cognetti D, et al. Tumor microenvironment in head and neck squamous cell carcinoma［J］. Semin Oncol, 2014, 41(2):217234. ［14］ Chung HW, Lim JB. Role of the tumor microenvironment in the pathogenesis of gastric carcinoma［J］. World J Gastroenterol, 2014, 20(7):16671680. ［15］ Gupta DK, Singh N, Sahu DK. TGFbeta mediated crosstalk between malignant hepatocyte and tumor microenvironment in hepatocellular carcinoma［J］. Cancer Growth Metastasis, 2014, 7:18. ［16］ Erez N, Truitt M, Olson P, et al. Cancerassociated fibroblasts are activated in incipient neoplasia to orchestrate tumorpromoting inflammation in an NFkappaBdependent manner［J］. Cancer Cell, 2010, 17(2):135147. ［17］ Balsamo M, Scordamaglia F, Pietra G, et al. Melanomaassociated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity［J］. Proc Natl Acad Sci U S A, 2009, 106(49):2084720852. ［18］ Calon A, Tauriello DV, Batlle E. TGFbeta in CAFmediated tumor growth and metastasis［J］. Semin Cancer Biol, 2014, 25:1522. ［19］ Reichl P, Haider C, Grubinger M, et al. TGFbeta in epithelial to mesenchymal transition and metastasis of liver carcinoma［J］. Curr Pharm Des, 2012, 18(27):41354147. ［20］潘漪莲. 上皮细胞间质转化与肿瘤［J］. 国际肿瘤学杂志, 2010, 37(5): 348351. ［21］强素凤, 黄勇. 上皮细胞间质转化与肿瘤干细胞［J］. 国际肿瘤学杂志, 2013, 40(3): 177180. ［22］ Eiró N, Vizoso FJ. Inflammation and cancer［J］. World J Gastrointest Surg, 2012, 4(3):6272. ［23］ Gong Y, ChippadaVenkata UD, Oh WK. Roles of matrix metalloproteinases and their natural inhibitors in prostate cancer progression［J］. Cancers (Basel), 2014, 6(3):12981327. ［24］ Zhao H, Yuan X, Jiang J, et al. Antimetastatic effects of licochalcone B on human bladder carcinoma T24 by inhibition of matrix metalloproteinases9 and NFκB activity［J］. Basic Clin Pharmacol Toxicol, 2014, 115(6): 527533.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua.Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy[J]. Journal of International Oncology, 2024, 51(5): 257-266.
[4]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[5]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei.Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction[J]. Journal of International Oncology, 2024, 51(4): 193-197.
[6]	Wan Fang, Yang Gang, Li Rui, Wan Qijing.Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer[J]. Journal of International Oncology, 2024, 51(4): 204-209.
[7]	Yao Yixin, Shen Yulin.Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE[J]. Journal of International Oncology, 2024, 51(4): 217-222.
[8]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao.Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes[J]. Journal of International Oncology, 2024, 51(3): 143-150.
[9]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan.Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 175-180.
[10]	Peng Qin, Cai Yuting, Wang Wei.Advances on KPNA2 in liver cancer[J]. Journal of International Oncology, 2024, 51(3): 181-185.
[11]	Chen Boguang, Wang Sugui, Zhang Yongjie.Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer[J]. Journal of International Oncology, 2024, 51(2): 73-82.
[12]	Jin Xudong, Chen Zhongjian, Mao Weimin.Research progress on the role of MTAP in malignant mesothelioma[J]. Journal of International Oncology, 2024, 51(2): 99-104.
[13]	Huang Zhen, Chen Yongshun.Research progress of circulating tumor DNA in the diagnosis and treatment of hepatocellular carcinoma[J]. Journal of International Oncology, 2024, 51(1): 59-64.
[14]	Wang Xiao, Li Ying, Luo Yujie, Jin Shu.Study on the prognostic value of serological indicators for nasopharyngeal carcinoma based on nomogram model[J]. Journal of International Oncology, 2023, 50(8): 463-469.
[15]	Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong.Expression and clinical significance of ASB6 in colorectal cancer tissues[J]. Journal of International Oncology, 2023, 50(8): 470-474.